Prolia®.
What is Prolia®? Since 2010 the active ingredient Denosumab is on the market, which is distributed by the company AMGEN under the trade names Prolia® and XGEVA®. The human monoclonal IgG2 anti-RANKL antibody is used for the treatment of bone loss (osteoporosis). The efficacy is achieved by Denosumab interfering with the so-called RANK/RANKL system of … Prolia®.